We are developing anti-inflammatory monoclonal antibodies with novel mechanisms of action.
Targeting oxLDL – a critical mediator of inflammation
Oxidized low density lipoprotein (oxLDL) is implicated in chronic, common conditions caused by inflammation such as such as cardiovascular disease, rheumatological disease and cancer. By targeting specific mechanisms of inflammation, Abcentra aims to treat a larger at-risk population – better.
Lead Candidate – Orticumab
Our lead candidate is the first and only fully-human monoclonal antibody of its kind targeting oxLDL:
- Being developed to treat plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid disease.
- Three clinical trials completed to date, demonstrating an excellent safety profile and has shown evidence of activity in humans.
- With strong scientific support, orticumab has been featured in several peer-reviewed scientific publications.
PRECLINICAL PROGRAM – LIPOPROTEIN(a) INHIBITION
- Lipoprotein(a) [or lp(a)] is an inflammatory lipoprotein consisting of an oxLDL-like particle and molecule of apolipoprotein(a).
- Elevated Lp(a) is associated with accelerated progression of aortic valve stenosis and an increased risk of heart attack.
- Abcentra is developing antibodies to treat aortic valve stenosis in patients with elevated lipoprotein(a) by inhibiting the assembly of lipoprotein(a).
Abcentra is developing a pipeline of therapeutic monoclonal antibodies against oxLDL. Current anti-inflammatory immunomodulatory drugs can effectively treat rheumatic diseases, but with serious side effects – including infections and cancers. We are developing a solution. See our pipeline for more information.